ScoreWhy is Shanghai MicuRx Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 44.52% and Operating profit at -14.61% over the last 5 years
3
Flat results in Jun 25
- INTEREST(HY) At CNY 6.32 MM has Grown at 26.01%
- ROCE(HY) Lowest at -78.12%
- DEBT-EQUITY RATIO (HY) Highest at -53.26 %
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 27.71%, its profits have risen by 25%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Shanghai MicuRx Pharmaceutical Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shanghai MicuRx Pharmaceutical Co., Ltd.
22.37%
1.07
51.96%
China Shanghai Composite
24.8%
1.73
14.01%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
44.52%
EBIT Growth (5y)
-14.61%
EBIT to Interest (avg)
-53.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0.15
Tax Ratio
1.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.70
EV to EBIT
-8.27
EV to EBITDA
-8.68
EV to Capital Employed
39.10
EV to Sales
22.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-473.03%
ROE (Latest)
-124.29%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
NET PROFIT(HY)
Higher at CNY -142.94 MM
RAW MATERIAL COST(Y)
Fallen by -10.91% (YoY
NET SALES(Q)
At CNY 33.7 MM has Grown at 21.55%
-11What is not working for the Company
INTEREST(HY)
At CNY 6.32 MM has Grown at 26.01%
ROCE(HY)
Lowest at -78.12%
DEBT-EQUITY RATIO
(HY)
Highest at -53.26 %
Here's what is working for Shanghai MicuRx Pharmaceutical Co., Ltd.
Net Profit
Higher at CNY -142.94 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CNY MM)
Net Sales
At CNY 33.7 MM has Grown at 21.55%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Raw Material Cost
Fallen by -10.91% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shanghai MicuRx Pharmaceutical Co., Ltd.
Interest
At CNY 6.32 MM has Grown at 26.01%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Debt-Equity Ratio
Highest at -53.26 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
